Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Thrombosis and Thrombolysis
Published in: Journal of Thrombosis and Thrombolysis 3/2013

01-04-2013

Sickle cell disease and venous thromboembolism: what the anticoagulation expert needs to know

Authors: Rakhi P. Naik, Michael B. Streiff, Sophie Lanzkron

Published in: Journal of Thrombosis and Thrombolysis | Issue 3/2013

Login to get access

Abstract

Venous thromboembolism (VTE) is common in patients with sickle cell disease (SCD). The etiology of increased risk of VTE in SCD patients is multifactorial and is related to both traditional factors and SCD-specific factors. Traditional risk factors such as central venous catheters, frequent hospitalization, orthopedic surgeries for avascular necrosis, and pregnancy may lead to increased incidence of VTE in the SCD population. In addition, SCD itself appears to be a hypercoagulable state, and many SCD-specific factors such as thrombophilic defects, genotype and splenectomy may modify the risk of VTE. SCD complications such as acute chest syndrome and pulmonary hypertension may also be related to VTE. Anticoagulation experts should be aware of these factors to help inform prophylaxis and treatment decisions.
Literature
1.
2.
Famodu AA, Oduwa D (1995) Platelet count and platelet factor 3 (PF-3) availability in sickle cell disease. Br J Biomed Sci 52(4):323–324PubMed
3.
Foulon I, Bachir D, Galacteros F, Maclouf J (1993) Increased in vivo production of thromboxane in patients with sickle cell disease is accompanied by an impairment of platelet functions to the thromboxane A2 agonist U46619. Arterioscler thromb 13(3):421–426PubMedCrossRef
4.
Kenny MW, George AJ, Stuart J (1980) Platelet hyperactivity in sickle-cell disease: a consequence of hyposplenism. J Clin Pathol 33(7):622–625PubMedCrossRef
5.
Westerman M, Pizzey A, Hirschman J et al (2008) Microvesicles in haemoglobinopathies offer insights into mechanisms of hypercoagulability, haemolysis and the effects of therapy. Br J Haematol 142(1):126–135PubMedCrossRef
6.
Westerman MP, Green D, Gilman-Sachs A et al (1999) Antiphospholipid antibodies, proteins C and S, and coagulation changes in sickle cell disease. J Lab Clin Med 134(4):352–362PubMedCrossRef
7.
Ataga KI, Orringer EP (2003) Hypercoagulability in sickle cell disease: a curious paradox. Am J Med 115(9):721–728PubMedCrossRef
8.
Chiu D, Lubin B, Roelofsen B, van Deenen LL (1981) Sickled erythrocytes accelerate clotting in vitro: an effect of abnormal membrane lipid asymmetry. Blood 58(2):398–401PubMed
9.
Villagra J, Shiva S, Hunter LA, Machado RF, Gladwin MT, Kato GJ (2007) Platelet activation in patients with sickle disease, hemolysis-associated pulmonary hypertension, and nitric oxide scavenging by cell-free hemoglobin. Blood 110(6):2166–2172PubMedCrossRef
10.
Ataga KI (2009) Hypercoagulability and thrombotic complications in hemolytic anemias. Haematologica 94(11):1481–1484PubMedCrossRef
11.
12.
Novelli EM, Huynh C, Gladwin MT, Moore CG, Ragni MV (2012) Pulmonary embolism in sickle cell disease: a case-control study. J Thromb Haemost 10:760–766PubMedCrossRef
13.
Stein PD, Beemath A, Meyers FA, Skaf E, Olson RE (2006) Deep venous thrombosis and pulmonary embolism in hospitalized patients with sickle cell disease. Am J Med 119(10):897.e7–897.e11CrossRef
14.
Lijfering WM, Brouwer JL, Veeger NJ et al (2009) Selective testing for thrombophilia in patients with first venous thrombosis: results from a retrospective family cohort study on absolute thrombotic risk for currently known thrombophilic defects in 2,479 relatives. Blood 113(21):5314–5322PubMedCrossRef
15.
Jeng MR, Feusner J, Skibola C, Vichinsky E (2002) Central venous catheter complications in sickle cell disease. Am J Hematol 69(2):103–108PubMedCrossRef
16.
Abdul-Rauf A, Gauderer M, Chiarucci K, Berman B (1995) Long-term central venous access in patients with sickle cell disease. incidence of thrombotic and infectious complications. J Pediatr Hematol Oncol 17(4):342–345PubMedCrossRef
17.
Alkindi S, Matwani S, Al-Maawali A, Al-Maskari B, Pathare A (2012) Complications of PORT-A-CATH((R)) in patients with sickle cell disease. J Infect Public Health 5(1):57–62PubMedCrossRef
18.
Raj A, Bertolone S, Bond S, Burnett D, Denker A (2005) Cathlink 20: a subcutaneous implanted central venous access device used in children with sickle cell disease on long-term erythrocytapheresis–a report of low complication rates. Pediatr Blood Cancer 44(7):669–672PubMedCrossRef
19.
Phillips G, Slingluff C, Hartman J, Thomas P, Akwari O (1988) Totally implantable intravenous catheters in the management of sickle cell anemia. Am J Hematol 29(3):134–138PubMedCrossRef
20.
Verso M, Agnelli G (2003) Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. J Clin Oncol 21(19):3665–3675PubMedCrossRef
21.
22.
Brousseau DC, Owens PL, Mosso AL, Panepinto JA, Steiner CA (2010) Acute care utilization and rehospitalizations for sickle cell disease. JAMA 303(13):1288–1294PubMedCrossRef
23.
Epstein K, Yuen E, Riggio JM, Ballas SK, Moleski SM (2006) Utilization of the office, hospital and emergency department for adult sickle cell patients: a five-year study. J Natl Med Assoc 98(7):1109–1113PubMed
24.
Gardner K, Bell C, Bartram JL et al (2010) Outcome of adults with sickle cell disease admitted to critical care - experience of a single institution in the UK. Br J Haematol 150(5):610–613PubMedCrossRef
25.
Vichinsky EP, Neumayr LD, Earles AN et al (2000) Causes and outcomes of the acute chest syndrome in sickle cell disease. national acute chest syndrome study group. N Engl J Med 342(25):1855–1865PubMedCrossRef
26.
Powars DR, Chan LS, Hiti A, Ramicone E, Johnson C (2005) Outcome of sickle cell anemia: a 4-decade observational study of 1,056 patients. Medicine (Baltimore) 84(6):363–376CrossRef
27.
Vichinsky EP, Neumayr LD, Haberkern C et al (1999) The perioperative complication rate of orthopedic surgery in sickle cell disease: report of the national sickle cell surgery study group. Am J Hematol 62(3):129–138PubMedCrossRef
28.
Adam S, Jonassaint J, Kruger H et al (2008) Surgical and obstetric outcomes in adults with sickle cell disease. Am J Med 121(10):916–921PubMedCrossRef
29.
Villers MS, Jamison MG, De Castro LM, James AH (2008) Morbidity associated with sickle cell disease in pregnancy. Am J Obstet Gynecol 199(2):125.e1–125.e5CrossRef
30.
James AH, Jamison MG, Brancazio LR, Myers ER (2006) Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality. Am J Obstet Gynecol 194(5):1311–1315PubMedCrossRef
31.
Kucuk O, Gilman-Sachs A, Beaman K, Lis LJ, Westerman MP (1993) Antiphospholipid antibodies in sickle cell disease. Am J Hematol 42(4):380–383PubMedCrossRef
32.
Olayemi EE, Bazuaye GN (2009) Lupus anticoagulant and leg ulcers in sickle cell anemia. Indian J Dermatol 54(3):251–254PubMedCrossRef
33.
Schnog JB (2004) Mac Gillavry MR, van Zanten AP, et al. Protein C and S and inflammation in sickle cell disease. Am J Hematol 76(1):26–32PubMedCrossRef
34.
Piccin A, Murphy C, Eakins E et al (2012) Protein C and free protein S in children with sickle cell anemia. Ann Hematol 91(10):1669–1671PubMedCrossRef
35.
Tam DA (1997) Protein C and protein S activity in sickle cell disease and stroke. J Child Neurol 12(1):19–21PubMedCrossRef
36.
Khanduri U, Gravell D, Christie BS, Al Lamki Z, Zachariah M, Cherian E (1998) Reduced protein C levels—a contributory factor for stroke in sickle cell disease. Thromb Haemost 79(4):879–880PubMed
37.
Porter JB, Young L, Mackie IJ, Marshall L, Machin SJ (1993) Sickle cell disorders and chronic intravascular haemolysis are associated with low plasma heparin cofactor II. Br J Haematol 83(3):459–465PubMedCrossRef
38.
Taher A, Isma’eel H, Mehio G et al (2006) Prevalence of thromboembolic events among 8,860 patients with thalassaemia major and intermedia in the mediterranean area and iran. Thromb Haemost 96(4):488–491PubMed
39.
Schilling RF, Gangnon RE, Traver MI (2008) Delayed adverse vascular events after splenectomy in hereditary spherocytosis. J Thromb Haemost 6(8):1289–1295PubMedCrossRef
40.
Cappellini MD (2007) Coagulation in the pathophysiology of hemolytic anemias. Hematol Am Soc Hematol Educ Program 2007:74–78CrossRef
41.
Taher AT, Musallam KM, Karimi M et al (2010) Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the optimal care study. Blood 115(10):1886–1892PubMedCrossRef
42.
Rogers ZR, Wang WC, Luo Z et al (2011) Biomarkers of splenic function in infants with sickle cell anemia: baseline data from the baby hug trial. Blood 117(9):2614–2617PubMedCrossRef
43.
Lane PA, O’Connell JL, Lear JL et al (1995) Functional asplenia in hemoglobin SC disease. Blood 85(8):2238–2244PubMed
44.
Kato GJ, Gladwin MT, Steinberg MH (2007) Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes. Blood Rev 21(1):37–47PubMedCrossRef
45.
Ballas SK, Lewis CN, Noone AM, Krasnow SH, Kamarulzaman E, Burka ER (1982) Clinical, hematological, and biochemical features of hb SC disease. Am J Hematol 13(1):37–51PubMedCrossRef
46.
Manci EA, Culberson DE, Yang YM et al (2003) Causes of death in sickle cell disease: an autopsy study. Br J Haematol 123(2):359–365PubMedCrossRef
47.
Mekontso Dessap A, Deux JF, Abidi N et al (2011) Pulmonary artery thrombosis during acute chest syndrome in sickle cell disease. Am J Respir Crit Care Med 184(9):1022–1029PubMedCrossRef
48.
Miller ST (2011) How I treat acute chest syndrome in children with sickle cell disease. Blood 117(20):5297–5305PubMedCrossRef
49.
Mehari A, Gladwin MT, Tian X, Machado RF, Kato GJ (2012) Mortality in adults with sickle cell disease and pulmonary hypertension. JAMA 307(12):1254–1256PubMedCrossRef
50.
Anthi A, Machado RF, Jison ML et al (2007) Hemodynamic and functional assessment of patients with sickle cell disease and pulmonary hypertension. Am J Respir Crit Care Med 175(12):1272–1279PubMedCrossRef
51.
Adedeji MO, Cespedes J, Allen K, Subramony C, Hughson MD (2001) Pulmonary thrombotic arteriopathy in patients with sickle cell disease. Arch Pathol Lab Med 125(11):1436–1441PubMed
52.
Jerath A, Murphy P, Madonik M, Barth D, Granton J, de Perrot M (2011) Pulmonary endarterectomy in sickle cell haemoglobin C disease. Eur Respir J 38(3):735–737PubMedCrossRef
53.
Haque AK, Gokhale S, Rampy BA, Adegboyega P, Duarte A, Saldana MJ (2002) Pulmonary hypertension in sickle cell hemoglobinopathy: a clinicopathologic study of 20 cases. Hum Pathol 33(10):1037–1043PubMedCrossRef
54.
Ataga KI, Moore CG, Hillery CA et al (2008) Coagulation activation and inflammation in sickle cell disease-associated pulmonary hypertension. Haematologica 93(1):20–26PubMedCrossRef
55.
Ataga KI, Key NS (2007) Hypercoagulability in sickle cell disease: new approaches to an old problem. Hematol Am Soc Hematol Educ Program 2007:91–96
56.
Kearon C, Akl EA, Comerota AJ et al (2012) Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest 141(2 Suppl):e419S–e494SPubMedCrossRef
57.
Qaseem A, Chou R, Humphrey LL, Starkey M, Shekelle P (2011) Clinical guidelines committee of the American college of physicians. venous thromboembolism prophylaxis in hospitalized patients: a clinical practice guideline from the american college of physicians. Ann Intern Med 155(9):625–632PubMed
58.
Falck-Ytter Y, Francis CW, Johanson NA et al (2012) Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest 141(2 Suppl):e278S–e325SPubMedCrossRef
59.
Bates SM (2011) Pregnancy-associated venous thromboembolism: prevention and treatment. Semin Hematol 48(4):271–284PubMedCrossRef
60.
Naik RP, Lanzkron S (2012) Baby on board: what you need to know about pregnancy in the hemoglobinopathies. Hematol Am Soc Hematol Educ Program 2012:208–214
61.
Kabrhel C, Mark Courtney D, Camargo CA et al (2010) Factors associated with positive D-dimer results in patients evaluated for pulmonary embolism. Acad Emerg Med 17(6):589–597PubMedCrossRef
62.
Colella MP, De Paula EV, Conran N et al (2012) Hydroxyurea is associated with reductions in hypercoagulability markers in sickle cell anemia. J Thromb Haemost 10(9):1967–1970PubMedCrossRef
Metadata
Title
Sickle cell disease and venous thromboembolism: what the anticoagulation expert needs to know
Authors
Rakhi P. Naik
Michael B. Streiff
Sophie Lanzkron
Publication date
01-04-2013
Publisher
Springer US
Published in
Journal of Thrombosis and Thrombolysis / Issue 3/2013
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-013-0895-y

Other articles of this Issue 3/2013

Journal of Thrombosis and Thrombolysis 3/2013 Go to the issue

OriginalPaper

Monitoring target specific anticoagulants

OriginalPaper

Top practice-changing articles over the last two years

OriginalPaper

Rationale supporting an “opt-out” policy for pharmacological venous thromboembolism prophylaxis in hospitalized medical patients

CME/CNE Article

Impact of target-specific oral anticoagulants on transitions of care and outpatient care models

OriginalPaper

Medical prophylaxis: the value of an “opt in” policy

OriginalPaper

Prevention of VTE in patients having major orthopedic surgery
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits